Top Stories
The US regulator has authorised EchoNext to detect six types of heart disease using standard 12-lead ECGs.
Over the last several months, the startup has grown its revenue five-fold, added more than 40 healthcare customers and expanded across over 150,000 healthcare providers.
The agreement comes shortly after Iambic inked a drug discovery deal with Takeda potentially worth more than $1.7 billion.
Partnership aims to discover and develop candidates for neuroimmune disorders with an unmet need.
The company's Body Scan scale measures fat and muscle mass percentages, giving obesity care teams more insight into a patient's health than just their weight.
Conference News
At HLTH Europe, executives from Sanofi, Takeda, MSD and TransCelerate came together in a panel discussion to compare notes on where the European pharma sector is at in its digital journey and how it compares with other regions on the global stage.
Showcasing how advanced AI models are transforming clinical development and accelerating precision medicineWALTHAM, Mass.--(BUSINESS WIRE)-- BostonGene, leading developer of AI models for tumor and im...
ASCO Perspective Quote“Prior studies on multi-cancer early detection tests have largely focused on Western populations. This large-scale study across 6 Asian countries showed the potential for cell-fr...
SEC-registered, FINRA-member platform expands capital access for life science innovatorsSAN DIEGO, CA, UNITED STATES, June 22, 2026 /EINPresswire.com/ -- BioTech Social Inc. (BSI) today announced the ...
Company to present data demonstrating increases in CSF HDL-like lipid transport proteins following Spectris™ therapyCAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cognito Therapeutics, a clinical-stage neurotech...
